EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry

Naoaki Ohkubo, Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Ryuichiro Kanda und 8 weitere

Modern Rheumatology · 04.11.2026 · 36 (6) · 1046-1054

DOI: 10.1093/mr/roag030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 16.03.2026. Verfasst von Naoaki Ohkubo und 19 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan. Hauptthemen laut MEDLINE: Polymyalgia Rheumatica, Antibodies, Monoclonal, Humanized, Antirheumatic Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grant-in-Aid for Scientific Research for Advanced Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis.

Methods

Using data from the FIRST registry, a cohort of patients initiating molecular targeted therapy for rheumatoid arthritis, we identified cases from 2003 to April 2024 in which sarilumab was introduced as the first biologic agent and PMR was concurrently diagnosed. As a control group, we selected patients hospitalized for a PMR flare during the same period who received the standard of care without biologic therapy. The primary outcome was the clinical PMR Activity Score at 52 weeks post-treatment initiation.

Results

Among 5645 registered cases, 67 patients were identified as having PMR with coexisting rheumatoid arthritis and received sarilumab as their initial biologic therapy. The control group comprised 76 patients treated with conventional therapy alone. The 52-weeks continuation rate of sarilumab was 77.5%, indicating high treatment persistence. At 52 weeks, clinical PMR Activity Score scores decreased in both groups. Logistic regression analysis using low disease activity at 52 weeks as the outcome revealed sarilumab use as a significant predictor. After adjusting for baseline differences using inverse probability weighting based on propensity scores, the sarilumab group showed a significantly greater reduction in the clinical PMR Activity Score compared to the standard of care group.

Conclusions

These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyalgia RheumaticaAntibodies, Monoclonal, HumanizedAntirheumatic AgentsHumansFemaleRegistriesRetrospective StudiesMaleAgedTreatment OutcomeArthritis, RheumatoidAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

Polymyalgia rheumaticabiologicsrheumatoid arthritissarilumab

Substanzen

Antibodies, Monoclonal, HumanizedAntirheumatic Agentssarilumab

Autor:innen und Institutionen

  • The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.
  • Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.
  • Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.
  • Department of Infectious Disease Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.

ORCID-Profile: Yoshiya Tanaka

Förderung

  • Grant-in-Aid for Scientific Research for Advanced Research

Zitieren

APA

Ohkubo, N., Miyazaki, Y., Kubo, S., Miyagawa, I., Sonomoto, K., Inoue, Y., Satoh-Kanda, Y., Tanaka, H., Ueno, M., Nagayasu, A., Aritomi, T., Kanda, R., Fujita, Y., Funada, M., Sakai, H., Yoshioka, K., Nishimoto, M., Takahashi, K., Nakayamada, S., & Tanaka, Y. (2026). Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry. Modern Rheumatology, 36(6), 1046-1054. https://doi.org/10.1093/mr/roag030

Vancouver

Ohkubo N, Miyazaki Y, Kubo S, Miyagawa I, Sonomoto K, Inoue Y, et al. Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry. Modern Rheumatology. 2026;36(6):1046-1054. doi:10.1093/mr/roag030

BibTeX
@article{Ohkubo2026,
  author = {Ohkubo, Naoaki and Miyazaki, Yusuke and Kubo, Satoshi and Miyagawa, Ippei and Sonomoto, Koshiro and Inoue, Yoshino and Satoh-Kanda, Yurie and Tanaka, Hiroaki and Ueno, Masanobu and Nagayasu, Atsushi and Aritomi, Takafumi and Kanda, Ryuichiro and Fujita, Yuya and Funada, Masashi and Sakai, Hidenori and Yoshioka, Kiyotake and Nishimoto, Mayu and Takahashi, Kazuki and Nakayamada, Shingo and Tanaka, Yoshiya},
  title = {Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry},
  journal = {Modern Rheumatology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {1046--1054},
  doi = {10.1093/mr/roag030}
}
Kostenlos starten →